SAB Biotherapeutics (SABS) to Release Earnings on Thursday

Posted by Defense World Staff on Aug 7th, 2025

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect SAB Biotherapeutics to post earnings of ($0.66) per share for the quarter.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.44. On average, analysts expect SAB Biotherapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SAB Biotherapeutics Price Performance

SABS opened at $2.19 on Thursday. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 0.15. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60. The company has a 50 day moving average of $2.10 and a two-hundred day moving average of $1.90. The company has a market cap of $20.35 million, a P/E ratio of -0.59 and a beta of 0.53.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SABS. HC Wainwright decreased their target price on shares of SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Chardan Capital restated a “buy” rating and issued a $20.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, May 15th.

Check Out Our Latest Analysis on SAB Biotherapeutics

SAB Biotherapeutics Company Profile

(Get Free Report)

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.